BCM
IOBT

Bridgeway Capital Management’s IO Biotech IOBT Stock Holding History

Bridgeway Capital Management’s Portfolio IOBT Stock Details IOBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-75,000
Closed -$45.7K – 1276
2025
Q4 		$45.7K Hold
75,000
– – ﹤0.01% 1185
2025
Q3 		$27.2K Hold
75,000
– – ﹤0.01% 1185
2025
Q2 		$104K Hold
75,000
– – ﹤0.01% 1066
2025
Q1 		$81.8K Sell
75,000
-99,000
-57% -$93.5K ﹤0.01% 1072
2024
Q4 		$160K Sell
174,000
-25,623
-13% -$25.5K ﹤0.01% 1046
2024
Q3 		$210K Buy
199,623
+75,000
+60% +$94.4K ﹤0.01% 1056
2024
Q2 		$146K Hold
124,623
– – ﹤0.01% 1115
2024
Q1 		$218K Sell
124,623
-20,577
-14% -$35.7K ﹤0.01% 1097
2023
Q4 		$273K Buy
145,200
+13,000
+10% +$15.5K 0.01% 1076
2023
Q3 		$182K Hold
132,200
– – ﹤0.01% 1125
2023
Q2 		$259K Hold
132,200
– – 0.01% 1074
2023
Q1 		$247K Hold
132,200
– – 0.01% 1063
2022
Q4 		$304K Buy
132,200
+36,300
+38% +$96.1K 0.01% 987
2022
Q3 		$260K Buy
95,900
+20,900
+28% +$77.5K 0.01% 1080
2022
Q2 		$350K Buy
+75,000
New +$459K 0.01% 962

Other funds holding IOBT

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return

Bridgeway Capital Management's IOBT Position: Q1 2026 in Review

Bridgeway Capital Management sold out of IO Biotech (IOBT) in Q1 2026, closing a stake of 75,000 shares — an estimated $45.7K sold.

Bridgeway Capital Management first reported a position in IOBT in Q2 2022 and held it in 15 quarters. The position peaked at $350K in Q2 2022. 12 funds tracked by Wall St. Rank hold IOBT as of Q1 2026.

  • Bridgeway Capital Management reported no remaining IO Biotech position as of Q1 2026 after selling out during the quarter.
  • Bridgeway Capital Management sold 75,000 IO Biotech shares in Q1 2026, an estimated $45.7K.
  • Bridgeway Capital Management first reported a position in IO Biotech in Q2 2022 and held it in 15 quarters.
  • Bridgeway Capital Management's IO Biotech position peaked at $350K in Q2 2022.
  • 12 funds tracked by Wall St. Rank held IO Biotech as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.